A late clinical trial TRACTION-2 using GFB-887, a podocyte targeted small molecule TRPC5 inhibitor, to treat diabetic kidney disease was designed based on previous in vitro and in vivo studies showing a protective effect of TRPC5 inhibition via the Rac1 signaling pathway (Walsh et al., 2021). Here, RAC1 is linked to diabetic kidney disease.